Medroxyprogesterone depot - Pfizer

Drug Profile

Medroxyprogesterone depot - Pfizer

Alternative Names: depo medroxyprogesterone acetate; Depo subQ in Uniject; Depo-subQ provera 104; DMPA -Pfizer; DMPA-SC; Medroxiprogesterone acetate; Sayana; Sayana Press; Sayana press

Latest Information Update: 10 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Antineoplastics; Hormonal replacements; Progesterone congeners; Progestogen-only oral contraceptives
  • Mechanism of Action Estradiol dehydrogenase modulators; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain; Pregnancy
  • Registered Endometriosis

Most Recent Events

  • 09 Dec 2015 Launched for Pregnancy (Prevention) in Bangladesh (SC) before December 2015
  • 08 Dec 2015 Launched for Pregnancy (Prevention) in Ireland, Czech Republic, Austria, Chile, Switzerland, Poland, Netherlands, Israel, Germany, Belgium (SC) before December 2015
  • 08 Dec 2015 Launched for Pregnancy (Prevention) in Puerto Rico, US Virgin Islands, USA (SC) before December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top